Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

Investors are expected to be cautious with CIPLA, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.928133
debtToEquity 1.621000
earningsGrowth 0.488000
revenueGrowth 0.070000
grossMargins 0.662630
operatingMargins 0.245510
trailingEps 61.740000
forwardEps 63.540000

CIPLA's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
With positive gross and operating margins, CIPLA demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
CIPLA's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that CIPLA is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

CIPLA's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


2 separate sales of CIPLA shares were executed, with the market price hovering at 1590.4249877929688.During the period under review, no sell transactions were recorded.The recent trend of increased buying at CIPLA's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


The analysts' recent buy bias for Cipla Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Cipla Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.